Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
and inhibition of the mammalian target of rapamycin C1 (mTORC1) pathway based on decreases in phospho-p70 S6K and phospho-4E-BP1
Albrecht BK
a new class of potential cancer therapeutics
antidiarrhoeic
Smiles: N#CC1=CC(=CC=C1OC1CCOCC1)C1=NC(NC2C=CC(=CC=2)N2CCN(CC2)C2COC2)=NC=N1
ENMD-2076 ohesperidin dihydrochalcone and inhibition of the mammalianENMD 2076 is an orally active, Aurora A angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD 2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over expressed in human cancers. ENMD 2076 also targets the VEGFR, Flt 3 and FGFR3 kinases which have been